+76%

est. 2Y upside i

HealthcareSeries A

Enabling next generation medicines. A comprehensive platform and…

Rank

#1002

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

64x Bio presents a moderate upside opportunity driven by its innovative VectorSelect™ platform and the recent launch of AAV Apex Suite, addressing a critical bottleneck in the large and growing gene therapy market.

Last updated: March 10, 2026

Bull (25%)+300%

The AAV Apex Suite achieves rapid market adoption and secures multiple high-value licensing deals with leading biopharma and CDMOs, significantly de-risking the platform and expanding into new therapeutic areas. Revenue grows to $50M+ by 2028, justifying a Series B or C valuation of $800M - $1B, reflecting strong execution and market leadership in viral vector manufacturing.

Base (46%)+50%

64x Bio successfully establishes its AAV Apex Suite in the market, securing a few key partnerships and demonstrating the value of its VectorSelect platform. Revenue grows steadily to $15M-$20M by 2028, leading to a modest Series B or C round at a valuation of $300M-$350M, reflecting continued progress but facing ongoing competitive pressures.

Bear (29%)-75%

Despite the launch of AAV Apex Suite, market adoption is slower than expected due to entrenched incumbents or unforeseen regulatory complexities. Revenue growth stagnates at $5M-$8M, leading to a challenging Series B fundraise or a down round, where the valuation drops to $50M-$60M, significantly eroding common stock value given the existing liquidation preferences.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $59.6M in liquidation preferences ahead of common stock, representing approximately 27.1% of the estimated current valuation of $220M.

Dilution Risk

moderate

Given the high capital intensity and early stage, future funding rounds (Series B, C) are highly likely within the next 1-2 years, leading to further dilution for existing equity holders.

Secondary Liquidity

none

As an early-stage company, there is currently no active secondary market or tender offer for 64x Bio's equity.

Questions to Ask at the Interview

Strategic questions based on 64x Bio's data — designed to show you've done your homework.

  • 1

    “With the launch of AAV Apex Suite and strategic collaborations, how is 64x Bio planning to differentiate its offerings and capture market share against established players like Cytiva and Lonza in the viral vector manufacturing space?”

  • 2

    “Given the high capital intensity of biotech and the current ~$4M revenue, what are the key milestones and revenue targets the company aims to achieve before its next funding round, and how will these demonstrate a clear path to profitability?”

  • 3

    “Considering the $59.6M in total funding and the estimated Series A valuation of $220M, how does the company envision the path to a liquidity event (IPO or acquisition) within the next 5-8 years, and what are the key value inflection points for common stock holders?”

Community

Valuation Sentiment

Our model estimates +76% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.